Emily J. Cox

Emily J. Cox

Auto-generated profile, based on publicly available information

Emily J. Cox

Providence Medical Research Center, Spokane, WA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in Journal of Addiction Medicine
Verified
Journal Article
Open access
HBHazel D. Brogdon
Hazel D. Brogdon
MMMackenzie M. McPhee
Mackenzie M. McPhee
MPMary Paine
Mary Paine
ECEmily J. Cox
Emily J. Cox
ABAmy G. Burns
Amy G. Burns
The botanical product kratom produces opioid-like effects at high doses and is sometimes used for opioid replacement by individuals with opioid use disorder. Mitragynine, a major alkaloid contained in kratom leaves, has been shown to inhibit multiple cytochromes P450 (CYPs) in vitro, including CYP2D6 and CYP3A. As such, kratom may precipitate pharmacokinetic drug interactions when co-consumed with certain medications. We present a case of a patient taking 150 mg venlafaxine (CYP2D6/3A substrate), 300 mg quetiapine (CYP3A substrate), and a high amount of kratom (~90 g) daily. The patient presented to the emergency department with serotonin syndrome and corrected electrocardiogram abnormalities that may have been secondary to supratherapeutic exposure to venlafaxine and/or quetiapine. The patient’s symptoms resolved after discontinuation of venlafaxine and quetiapine. He was amenable to medication therapy for kratom discontinuation and successfully completed an at-home induction with buprenorphine/naloxone. This case report adds to the literature about potential pharmacokinetic kratom-drug interactions and suggests that buprenorphine/naloxone can facilitate recovery from kratom use disorder.

7 January 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
KVKyle B Varner
Kyle B Varner
ECEmily J Cox
Emily J Cox
COVID-19 has serious thrombotic complications in critically ill patients; however, thrombus is not a typical presenting symptom. This case report describes a patient with no respiratory symptoms who presented to the emergency department with abdominal pain. The pain was attributed to renal thrombosis, but the patient was found to have no risk factors for thrombotic disease and subsequent hypercoagulable work-up was unremarkable. Pulmonary manifestations of COVID-19 infection were detected incidentally on the abdominal CT scan and confirmed via PCR test. The patient was isolated and went on to develop mild respiratory failure secondary to COVID-19 infection. This case suggests that unexplained thrombus in otherwise asymptomatic patients can be a direct result of COVID-19 infection, and serves as a call to action for emergency department clinicians to treat unexplained thrombotic events as evidence of COVID-19.

6 September 2021 in The Ultrasound Journal
Verified
Journal Article
Open access
PDF file
MWMichael H. Walsh
Michael H. Walsh
KZKang X. Zhang
Kang X. Zhang
ECEmily J. Cox
Emily J. Cox
JCJustin M. Chen
Justin M. Chen
NCNicholas G. Cowley
Nicholas G. Cowley
IMIrene W. Y. Ma
Irene W. Y. Ma
Background: In detecting pleural effusion, bedside ultrasound (US) has been shown to be more accurate than auscultation. However, US has not been previously compared to the comprehensive physical examination. This study seeks to compare the accuracy of physical examination with bedside US in detecting pleural effusion. Methods: This study included a convenience sample of 34 medical inpatients from Calgary, Canada and Spokane, USA, with chest imaging performed within 24 h of recruitment. Imaging results served as the reference standard for pleural effusion. All patients underwent a comprehensive lung physical examination and a bedside US examination by two researchers blinded to the imaging results. Results: Physical examination was less accurate than US (sensitivity of 44.0% [95% confidence interval (CI) 30.0–58.8%], specificity 88.9% (95% CI 65.3–98.6%), positive likelihood (LR) 3.96 (95% CI 1.03–15.18), negative LR 0.63 (95% CI 0.47–0.85) for physical examination; sensitivity 98% (95% CI 89.4–100%), specificity 94.4% (95% CI 72.7–99.9%), positive LR 17.6 (95% CI 2.6–118.6), negative LR 0.02 (95% CI 0.00–0.15) for US). The percentage of examinations rated with a confidence level of 4 or higher (out of 5) was higher for US (85% of the seated US examination and 94% of the supine US examination, compared to 35% of the PE, P < 0.001), and took less time to perform ( P < 0.0001). Conclusions: US examination for pleural effusion was more accurate than the physical examination, conferred higher confidence, and required less time to complete.

25 August 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Open access
PDF file
CMCarmen V. McDermott
Carmen V. McDermott
ECEmily J. Cox
Emily J. Cox
JSJames M. Scanlan
James M. Scanlan
RARadica Z. Alicic
Radica Z. Alicic
Fever and respiratory tract symptoms were highlighted early in the COVID-19 outbreak and are widely considered to be the main symptoms of COVID-19. As the outbreak has evolved, GI tract complaints (notably vomiting, diarrhea, anorexia, and abdominal pain) have emerged as prevalent symptoms, which sometimes occur in the absence of non-GI tract symptoms. Compared with SARS coronavirus (SARS-CoV) 1 or MERS coronavirus, in which GI tract symptoms occurred in approximately one-quarter of infected patients, Xie M. Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020; 94 : 119-124 Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar rates of GI tract symptoms may be lower for SARS-CoV-2, though prevalence data is still evolving and highly variable. Recent analyses describing the pooled prevalence of GI tract symptoms are summarized in Table 1. Combined results of these meta-analyses suggest that the “true” population rate of GI tract symptoms in patients with COVID-19 is likely between 10% and 20%. Table 1 Pooled Prevalence of GI Tract Symptoms From COVID-19 Meta-analyses Variable Parasa et al Parasa S. Desai M. Thoguluva Chandrasekar V. et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis. JAMA Netw Open. 2020; 3 : e2011335 Crossref PubMed Scopus (20) Google Scholar Cheung et al Cheung K.S. Hung I.F.N. Chan P.P. et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology. 2020; 159 : 81-95 Abstract Full Text Full Text PDF PubMed Google Scholar Tariq et al Tariq R. Saha S. Furqan F. Hassett L. Pardi D. Khanna S. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020; 95 : 1632-1648 Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar Mao et al Mao R. Qiu Y. He J.S. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020;5(7):e6]. Lancet Gastroenterol Hepatol. 2020; 5 : 667-678 Abstract Full Text Full Text PDF PubMed Scopus (84) Google Scholar No. of studies 29 60 78 35 No. of patients 4805 4243 12,797 6686 All GI tract symptoms NA 18% NA 15% Diarrhea 7% 13% 12% 9% Nausea/vomiting 5% 10% (vomiting) 9% 6% Abdominal pain NA 9% 6% 3% Liver injury 20% AST, 15% ALT NA NA 3% Anorexia NA 27% 22% 21% Stool sample positivity 41% 48.1% NA 54% ALT = alanine aminotransferase; AST = aspartate aminotransferase; COVID = coronavirus disease 2019; GI = gastrointestinal. Open table in a new tab

8 November 2023 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
JMJames C. Miller
James C. Miller
MBMichael A. Brooks
Michael A. Brooks
KWKelly E. Wurzel
Kelly E. Wurzel
ECEmily J. Cox
Emily J. Cox
JWJohn F. Wurzel
John F. Wurzel
Buprenorphine has become an important medication in the context of the ongoing opioid epidemic. However, complex pharmacologic properties and varying government regulations create barriers to its use. This narrative review is intended to facilitate buprenorphine use—including non-traditional initiation methods—by providers ranging from primary care providers to addiction specialists. This article briefly discusses the opioid epidemic and the diagnosis and treatment of opioid use disorder (OUD). We then describe the basic and complex pharmacologic properties of buprenorphine, linking these properties to their clinical implications. We guide readers through the process of initiating buprenorphine in patients using full agonist opioids. As there is no single recommended approach for buprenorphine initiation, we discuss the details, advantages, and disadvantages of the standard, low-dose, bridging-strategy, and naloxone-facilitated initiation techniques. We consider the pharmacology of, and evidence base for, buprenorphine in the treatment of pain, in both OUD and non-OUD patients. Throughout, we address the use of buprenorphine in children and adolescent patients, and we finish with considerations related to the settings of pregnancy and breastfeeding.

19 May 2022 in Journal of Invasive Cardiology
Verified
Journal Article
Closed access
RJRuyun Jin
Ruyun Jin
ECEmily Cox
Emily Cox
BRBranden Reynolds
Branden Reynolds
BCBrydan Curtis
Brydan Curtis
RHRobert Hodson
Robert Hodson
MRMichael Ring
Michael Ring
The authors compared echocardiographic and clinical outcomes in patients with SAA undergoing TAVR with either the ES23 or ME26 between July 2015 and December 2018.